GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Total Long-Term Assets

Incanthera (AQSE:INC) Total Long-Term Assets : £0.06 Mil (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Incanthera Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Incanthera's Total Long-Term Assets for the quarter that ended in Sep. 2023 was £0.06 Mil.


Incanthera Total Long-Term Assets Historical Data

The historical data trend for Incanthera's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Total Long-Term Assets Chart

Incanthera Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Total Long-Term Assets
0.79 0.66 0.54 0.06

Incanthera Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Total Long-Term Assets Get a 7-Day Free Trial 0.53 0.54 0.41 0.06 0.06

Incanthera Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


Incanthera Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Incanthera's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Incanthera (AQSE:INC) Business Description

Traded in Other Exchanges
N/A
Address
76 King Street, Manchester, GBR, M2 4NH
Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines